AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31379269 — intervention group
Group type: COMPARATOR
Intervention: Placebo (20 g of maltodextrin)
Number of subjects: 75
Study 29161113 — intervention group
Group type: EXPERIMENTAL
Intervention: Cogmed
Number of subjects: 68
Study 29161113 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 68
Study 29231426 — intervention group
Group type: EXPERIMENTAL
Intervention: Row acupuncture at the gaps between phalanges (group A)
Number of subjects: 71
Study 29231426 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy (group B)
Number of subjects: 71
Study 25467221 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabilone (NAB) 0.5 mg to 3.0 mg
Number of subjects: 10
Study 25467221 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 10
Study 25467221 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabilone (NAB)
Number of subjects: 10
Study 23246307 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP-IPV-Hep B-PRP-T vaccine (Hexaxim)
Number of subjects: 1270
Study 21586234 — intervention group
Group type: EXPERIMENTAL
Intervention: Telbivudine 600 mg daily for 52 weeks
Number of subjects: 180
Study 21586234 — intervention group
Group type: COMPARATOR
Intervention: Entecavir 0.5 mg daily for 52 weeks
Number of subjects: 180
Study 18363087 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mm tip radiofrequency (RF) ablation
Number of subjects: 62
Study 18363087 — intervention group
Group type: COMPARATOR
Intervention: Cryocatheter (cryo) ablation
Number of subjects: 62
Study 18363087 — intervention group
Group type: EXPERIMENTAL
Intervention: Both RF and cryo ablation
Number of subjects: 62
Study 16549733 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics (3 doses of 1200 mg intravenous amoxicillin-clavulanate at induction and 6 and 12 hours postoperatively)
Number of subjects: 164
Study 16549733 — intervention group
Group type: COMPARATOR
Intervention: Postoperative antibiotics (7-day course of 375 mg amoxicillin-clavulanate 3 times a day)
Number of subjects: 164
Study 14581419 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term adjuvant androgen deprivation (LTAD) with goserelin for 24 months after initial AD with external-beam radiotherapy (RT)
Number of subjects: 1554
Study 14581419 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term adjuvant androgen deprivation (LTAD) with goserelin for 24 months after initial AD with external-beam radiotherapy (RT) in patients with Gleason scores of 8 to 10
Number of subjects: 1554
Study 14581419 — intervention group
Group type: COMPARATOR
Intervention: Short-term adjuvant androgen deprivation with radiotherapy (STAD-RT)
Number of subjects: 1554
Study 10956572 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS
Number of subjects: 29
Study 8781792 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic heat probe therapy (median 165 J) at 24 hours
Number of subjects: 40
Study 8781792 — intervention group
Group type: COMPARATOR
Intervention: No retreatment
Number of subjects: 40
Study 1627435 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with oral LMF (fluorouracil, 500 mg, methotrexate, 25 mg, and chlorambucil, 10 mg, on day 1; fluorouracil, 500 mg, and chlorambucil, 10 mg, on day 2)
Number of subjects: 574
Study 1627435 — intervention group
Group type: COMPARATOR
Intervention: Control group (no further treatment)
Number of subjects: 574
Study 1627435 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with oral LMF
Number of subjects: 574
Study 1627435 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis of various prognostic factors
Number of subjects: 574
Study 6547563 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,25-dihydroxycholecalciferol (1,25(OH)2D3)
Number of subjects: 2
Study 6547563 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestrogen/gestagen treatment
Number of subjects: 2
Study 6547563 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 2
Study 3532401 — intervention group
Group type: EXPERIMENTAL
Intervention: Chrysanol (calcium‐aurothiopropanol‐sulfonate) plus nonsteroid antiinflammatory drugs (NAD)
Number of subjects: 21
Study 3532401 — intervention group
Group type: COMPARATOR
Intervention: Control group (NAD only)
Number of subjects: 21
Study 29369123 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet computer (intervention group)
Number of subjects: 82
Study 29369123 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 82
Study 27679965 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic Hypothermia after Pediatric Cardiac Arrest Out‐of‐Hospital trial
Number of subjects: 295
Study 23780517 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual education on pulse palpation by a trained nurse
Number of subjects: 205
Study 23372088 — intervention group
Group type: EXPERIMENTAL
Intervention: Facial cues associated with perceived height and masculinity in wartime context
Number of subjects: 0
Study 23372088 — intervention group
Group type: COMPARATOR
Intervention: Facial cues associated with perceived height and masculinity in peacetime context
Number of subjects: 0
Study 23372088 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing cues of apparent height and masculinity in faces
Number of subjects: 0
Study 20385692 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 min training with verbal feedback
Number of subjects: 43
Study 20385692 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 min training with verbal feedback
Number of subjects: 43
Study 27950666 — intervention group
Group type: COMPARATOR
Intervention: Concomitant CT/RT (Arm A)
Number of subjects: 101
Study 27950666 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with TPF followed by concomitant CT/RT (Arm B)
Number of subjects: 101
Study 16629429 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary inpatient rehabilitation for an average of 35.5 days
Number of subjects: 90
Study 16629429 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 90
Study 14974922 — intervention group
Group type: EXPERIMENTAL
Intervention: GH treatment (33 microg/kg/day)
Number of subjects: 87
Study 14974922 — intervention group
Group type: COMPARATOR
Intervention: GH treatment (66 microg/kg/day)
Number of subjects: 87
Study 10826408 — intervention group
Group type: COMPARATOR
Intervention: Diet 2: L‐arginine enriched by natural foods
Number of subjects: 6
Study 10826408 — intervention group
Group type: COMPARATOR
Intervention: Diet 3: identical to Diet 1 plus oral L‐arginine supplement
Number of subjects: 6
Study 8649712 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily gentamicin dosing (5 mg/kg)
Number of subjects: 127
Study 8649712 — intervention group
Group type: COMPARATOR
Intervention: 8-hour gentamicin dosing (1.75 mg/kg every 8 hours)
Number of subjects: 127
Study 1341599 — intervention group
Group type: COMPARATOR
Intervention: Nicotine polacrilex 0 mg (placebo)
Number of subjects: 35
Study 1341599 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine polacrilex 2 mg
Number of subjects: 35
Study 1341599 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine polacrilex 4 mg
Number of subjects: 35
Study 6149772 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine 30 mg
Number of subjects: 10
Study 29952863 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) delivered at 120% motor threshold, 10 Hz, 5-second train duration, and 10-second intertrain interval for 30 minutes weekly for 5 weeks (30,000 stimuli)
Number of subjects: 8
Study 29952863 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 8
Study 29952863 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Number of subjects: 8
Study 30031385 — intervention group
Group type: EXPERIMENTAL
Intervention: 10th IRSD decile (least disadvantaged)
Number of subjects: 300
Study 27615005 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning group (MG, 9:00‐11:00 AM)
Number of subjects: 67
Study 27615005 — intervention group
Group type: COMPARATOR
Intervention: Evening group (EG, 9:00‐11:00 PM)
Number of subjects: 67
Study 24350804 — intervention group
Group type: EXPERIMENTAL
Intervention: REQ-Mobile (smartphone application)
Number of subjects: 102
Study 24350804 — intervention group
Group type: COMPARATOR
Intervention: onQ (text messaging system)
Number of subjects: 102
Study 24350804 — intervention group
Group type: EXPERIMENTAL
Intervention: Both services (REQ-Mobile and onQ)
Number of subjects: 102
Study 22954866 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV prevention or general health intervention using social networking technologies
Number of subjects: 0
Study 20102867 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 2340
Study 20102867 — intervention group
Group type: COMPARATOR
Intervention: TIMI risk score alone
Number of subjects: 2340
Study 20102867 — intervention group
Group type: EXPERIMENTAL
Intervention: TIMI risk score with STRes added
Number of subjects: 2340
Study 20102867 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclusion of STRes to TIMI risk score
Number of subjects: 2340
Study 20102867 — intervention group
Group type: EXPERIMENTAL
Intervention: STRes in ExTRACT-TIMI 25 trial
Number of subjects: 2340
Study 18407386 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of MenC conjugate vaccine
Number of subjects: 0
Study 18407386 — intervention group
Group type: EXPERIMENTAL
Intervention: Three doses of MenC conjugate vaccine
Number of subjects: 0
Study 15764631 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 6%
Number of subjects: 55
Study 15764631 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 55
Study 12365325 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunocorrecting treatment with leukinferone
Number of subjects: 0
Study 12365325 — intervention group
Group type: COMPARATOR
Intervention: Etiotropic therapy
Number of subjects: 0
Study 9676889 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.85 g/kg)
Number of subjects: 115
Study 9676889 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study 7978173 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg)
Number of subjects: 271
Study 7978173 — intervention group
Group type: COMPARATOR
Intervention: Droperidol (1.25 mg)
Number of subjects: 271
Study 7978173 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 271
Study 2644749 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 ml of glucose-free 2% lignocaine
Number of subjects: 64
Study 2644749 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 ml of glucose-free 2% lignocaine
Number of subjects: 64
Study 2644749 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 ml of glucose-free 2% lignocaine
Number of subjects: 64
Study 2644749 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-4 ml of glucose-free 2% lignocaine
Number of subjects: 64
Study 2644749 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher doses of glucose-free 2% lignocaine
Number of subjects: 64
Study 2644749 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher cephalad spread of analgesia
Number of subjects: 64
Study 2644749 — intervention group
Group type: EXPERIMENTAL
Intervention: Falls in systolic blood pressure greater than 30%
Number of subjects: 64
Study 766574 — intervention group
Group type: EXPERIMENTAL
Intervention: practolol, 15 mg
Number of subjects: 20
Study 766574 — intervention group
Group type: COMPARATOR
Intervention: saline (placebo)
Number of subjects: 20
Study 31695330 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic formulation under fasting conditions
Number of subjects: 49
Study 31695330 — intervention group
Group type: COMPARATOR
Intervention: Branded formulation under fasting conditions
Number of subjects: 49
Study 31695330 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic formulation under fed conditions
Number of subjects: 49
Study 31695330 — intervention group
Group type: COMPARATOR
Intervention: Branded formulation under fed conditions
Number of subjects: 49
Study 31695330 — intervention group
Group type: EXPERIMENTAL
Intervention: Food intake before administration
Number of subjects: 49
Study 29998506 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-HTx sST2 levels ≥35 ng/mL (Group 2)
Number of subjects: 62
Study 29998506 — intervention group
Group type: COMPARATOR
Intervention: Post-HTx sST2 levels <35 ng/mL (Group 1)
Number of subjects: 62
Study 29998506 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-HTx sST2 levels
Number of subjects: 62
Study 26897268 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleated red blood cell (NRBC) count in patients with HDP
Number of subjects: 282
Study 26897268 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic/diastolic (S/D) ratios of fetal ductus venosus, umbilical artery and middle cerebral artery
Number of subjects: 282
Study 26897268 — intervention group
Group type: EXPERIMENTAL
Intervention: NRBC count and S/D ratios in diagnosing HDP
Number of subjects: 282
Study 26897268 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of NRBC and S/D ratios with various clinical parameters
Number of subjects: 282
Study 26897268 — intervention group
Group type: EXPERIMENTAL
Intervention: NRBC count
Number of subjects: 282
Study 24176780 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 minutes/day, 6 days/week of moderate-to-vigorous intensity exercise
Number of subjects: 100
Study 22079927 — intervention group
Group type: COMPARATOR
Intervention: 10-mg hydrocortisone
Number of subjects: 0
Study 18752726 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg/d)
Number of subjects: 42
Study 18752726 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine (8 mg/d)
Number of subjects: 42
Study 18752726 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 17513631 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (1.5 microg/mL)
Number of subjects: 15
Study 17513631 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (0.05 microg x kg(‐1) x min(‐1))
Number of subjects: 15
Study 17513631 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (0.025 microg x kg(‐1) x min(‐1))
Number of subjects: 15
Study 17513631 — intervention group
Group type: COMPARATOR
Intervention: Control (no propofol or remifentanil)
Number of subjects: 15
Study 15204248 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump CABG (OPCAB)
Number of subjects: 52
Study 15204248 — intervention group
Group type: COMPARATOR
Intervention: On-pump CABG (CPB)
Number of subjects: 52
Study 15204248 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 52
Study 11579243 — intervention group
Group type: EXPERIMENTAL
Intervention: Substituted protease inhibitor(s) with abacavir, nevirapine, adefovir and hydroxyurea (n = 49)
Number of subjects: 81
Study 11579243 — intervention group
Group type: COMPARATOR
Intervention: Continued all therapy (n = 32)
Number of subjects: 81
Study 9360756 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine (10 mg OD)
Number of subjects: 0
Study 9360756 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine (10 mg OD)
Number of subjects: 0
Study 9360756 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated patients)
Number of subjects: 0
Study 8250311 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 micrograms of clonidine (2-2.5 micrograms/kg)
Number of subjects: 60
Study 8250311 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 micrograms of clonidine (4-4.5 micrograms/kg)
Number of subjects: 60
Study 8250311 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 3319648 — intervention group
Group type: EXPERIMENTAL
Intervention: Glipizide treatment for 8 weeks
Number of subjects: 0
Study 3319648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30511959 — intervention group
Group type: COMPARATOR
Intervention: Control group (34 patients with cervical trauma)
Number of subjects: 90
Study 30511959 — intervention group
Group type: EXPERIMENTAL
Intervention: Degeneration group and herniation group
Number of subjects: 90
Study 30511959 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild, moderate, and severe groups (based on preoperative JOA scores)
Number of subjects: 90
Study 28784142 — intervention group
Group type: EXPERIMENTAL
Intervention: Accountable Care Condition (4 clinics, 16 CHW)
Number of subjects: 900
Study 28784142 — intervention group
Group type: COMPARATOR
Intervention: Standard Care Condition (4 clinics, 21 CHW)
Number of subjects: 900
Study 25330096 — intervention group
Group type: EXPERIMENTAL
Intervention: Agomelatine (single-dose)
Number of subjects: 124
Study 25330096 — intervention group
Group type: COMPARATOR
Intervention: Placebo (single-dose)
Number of subjects: 124
Study 23522121 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide QW
Number of subjects: 641
Study 20813349 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride Gel followed by no rinsing for 30 minutes
Number of subjects: 10
Study 20813349 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride Foam followed by no rinsing for 30 minutes
Number of subjects: 10
Study 20813349 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride Gel followed by rinsing with water
Number of subjects: 10
Study 20813349 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride Foam followed by rinsing with water
Number of subjects: 10
Study 20813349 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 19120502 — intervention group
Group type: EXPERIMENTAL
Intervention: Replacement of unflued gas heaters with more effective, non-polluting heaters
Number of subjects: 350
Study 19120502 — intervention group
Group type: COMPARATOR
Intervention: Unflued gas heaters
Number of subjects: 350
Study 19120502 — intervention group
Group type: COMPARATOR
Intervention: Gas stove-tops
Number of subjects: 350
Study 19120502 — intervention group
Group type: COMPARATOR
Intervention: Heat pumps, flued gas heating, or enclosed wood burners
Number of subjects: 350
Study 16290290 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg atorvastatin for 6 weeks
Number of subjects: 80
Study 16290290 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 80
Study 14551554 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 10965647 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week treatment condition (applied relaxation and problem solving via the Internet and E-mail)
Number of subjects: 102
Study 10965647 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 102
Study 8991751 — intervention group
Group type: EXPERIMENTAL
Intervention: Promotion program intervention in 28 nursing homes, including presentations by post-graduate medical students to nursing personnel and residents.
Number of subjects: 55
Study 8991751 — intervention group
Group type: COMPARATOR
Intervention: Control group (remaining nursing homes not receiving the intervention).
Number of subjects: 55
Study 8198213 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (0.6 g/kg)
Number of subjects: 12
Study 8198213 — intervention group
Group type: EXPERIMENTAL
Intervention: 4‐hr TIB and ethanol
Number of subjects: 12
Study 8198213 — intervention group
Group type: COMPARATOR
Intervention: 4‐hr TIB and placebo
Number of subjects: 12
Study 8198213 — intervention group
Group type: COMPARATOR
Intervention: 8‐hr TIB and placebo
Number of subjects: 12
Study 8198213 — intervention group
Group type: EXPERIMENTAL
Intervention: 8‐hr TIB and ethanol
Number of subjects: 12
Study 3478440 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate
Number of subjects: 24
Study 3478440 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid (betamethasone)
Number of subjects: 24
Study 31786121 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab plus nab-paclitaxel
Number of subjects: 902
Study 31786121 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus nab-paclitaxel
Number of subjects: 902
Study 29018885 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting Plasma Glucose (FPG)
Number of subjects: 1349
Study 29018885 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 h post-load glucose (2hPG)
Number of subjects: 1349
Study 29018885 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c
Number of subjects: 1349
Study 29018885 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting Insulin
Number of subjects: 1349
Study 29018885 — intervention group
Group type: EXPERIMENTAL
Intervention: HOMA-IR
Number of subjects: 1349
Study 28514277 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive choice arm (commitment contract with $30 payment conditional on visit and adherence)
Number of subjects: 110
Study 28514277 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider visit incentive arm ($30 after attending each scheduled provider visit)
Number of subjects: 110
Study 28514277 — intervention group
Group type: COMPARATOR
Intervention: Passive control arm (routine care with no incentives)
Number of subjects: 110
Study 25168918 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster dose of influenza vaccination administered 5 weeks after standard vaccination
Number of subjects: 514
Study 25168918 — intervention group
Group type: COMPARATOR
Intervention: Standard single dose of influenza vaccination
Number of subjects: 514
Study 22402056 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 mg daily
Number of subjects: 14264
Study 22402056 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (adjusted dose, INR 2.0-3.0)
Number of subjects: 14264
Study 20639824 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium 0.1% eye drop - 1 drop 4 times daily for 30 days after cataract surgery
Number of subjects: 80
Study 20639824 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone acetate 1% eye drop - 1 drop 2 hourly for 1 week, then 1 drop 4 hourly for 2 weeks, then 1 drop 6 hourly for 30 days after cataract surgery
Number of subjects: 80
Study 20639824 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium 0.1% eye drop
Number of subjects: 80
Study 20639824 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone acetate 1% eye drop
Number of subjects: 80
Study 20639824 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual acuity with pin hole in group-A
Number of subjects: 80
Study 20639824 — intervention group
Group type: COMPARATOR
Intervention: Visual acuity with pin hole in group-B
Number of subjects: 80